NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis $3.08 -0.14 (-4.35%) (As of 05:39 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vivos Therapeutics alerts: Email Address About Vivos Therapeutics Stock (NASDAQ:VVOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vivos Therapeutics alerts:Sign Up Key Stats Today's Range$2.78▼$3.3350-Day Range$2.01▼$4.1352-Week Range$1.91▼$48.79Volume880,259 shsAverage Volume548,005 shsMarket Capitalization$9.94 millionP/E RatioN/ADividend YieldN/APrice Target$6.60Consensus RatingBuy Company OverviewVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Read More… AI expert reveals new Nvidia prediction (Ad)Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why Vivos Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 57th PercentileVivos Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 446th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVivos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVivos Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Vivos Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos Therapeutics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVivos Therapeutics has a P/B Ratio of 13.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vivos Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.78% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently decreased by 34.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos Therapeutics does not currently pay a dividend.Dividend GrowthVivos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.78% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently decreased by 34.90%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.56 News SentimentVivos Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Vivos Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for VVOS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of Vivos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 26.35% of the stock of Vivos Therapeutics is held by institutions.Read more about Vivos Therapeutics' insider trading history. Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VVOS Stock News HeadlinesTinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct OfferingSeptember 20 at 8:28 AM | msn.comVivos Therapeutics Shares Drop 27% After Pricing of Common Stock OfferingSeptember 19 at 4:19 PM | marketwatch.comOur #1 Ticker for the Rare "Retirement Window"We've only seen this happen three times in the past 20 years... And every time - like clockwork - it's minted an entire new class of millionaires.September 20, 2024 | Behind the Markets (Ad)Vivos Therapeutics Offers Of 1.363 Mln Shares At $3.15/share, Pre-Market Stock DownSeptember 19 at 4:19 PM | markets.businessinsider.comWhy Vivos Therapeutics (VVOS) Stock Is Down 25% TodaySeptember 19 at 4:19 PM | msn.comVivos Therapeutics raises $4.3 from institutional investorsSeptember 19 at 8:36 AM | proactiveinvestors.comVivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesSeptember 19 at 7:37 AM | finance.yahoo.comVivos Therapeutics, Inc: Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and SnoringSeptember 18 at 10:51 AM | finanznachrichten.deSee More Headlines VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed this year? Vivos Therapeutics' stock was trading at $12.44 on January 1st, 2024. Since then, VVOS shares have decreased by 76.5% and is now trading at $2.92. View the best growth stocks for 2024 here. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.60) earnings per share for the quarter. The company had revenue of $4.05 million for the quarter. Vivos Therapeutics had a negative trailing twelve-month return on equity of 652.32% and a negative net margin of 85.90%. When did Vivos Therapeutics' stock split? Vivos Therapeutics shares reverse split before market open on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/14/2024Today9/20/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$6.60 High Stock Price Target$6.60 Low Stock Price Target$6.60 Potential Upside/Downside+108.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($10.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,580,000.00 Net Margins-85.90% Pretax Margin-85.90% Return on Equity-652.32% Return on Assets-98.95% Debt Debt-to-Equity RatioN/A Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$14.02 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book14.36Miscellaneous Outstanding Shares3,227,000Free Float2,917,000Market Cap$10.20 million OptionableOptionable Beta7.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:VVOS) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.